bs-0746R-Cy3 [Conjugated Primary Antibody]
HHV8 ORF50 Polyclonal Antibody, Cy3 Conjugated
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: HHV8 ORF50

Immunogen Range: 2-100/691


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 4961526

Swiss Prot: F5HCV3

Source: KLH conjugated synthetic peptide derived from N-terminus of HHV8 ORF50 strain GK18

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Background:

HHV8 has been found to be associated with three different diseases observed in AIDS patients; kaposi's sarcoma, primary effusion lymphoma (which is a rare type of non-Hodgkin lymphoma affecting the body cavities) and multicentric Castleman's disease. To date there is much evidence to support a direct role for HHV8 in kaposi's sarcoma.

Conjugation: Cy3

Excitation/ Emission: 512,550nm/570,615nm

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:500-1000)

Predicted Molecular Weight: 74


Cross Reactive Species: Virus
(Human herpesvirus 8, Kaposi's sarcoma-associated herpesvirus)

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Myung-Ju Lee. et al. CXCL1 confers a survival advantage in Kaposi's sarcoma-associated herpesvirus-infected human endothelial cells through STAT3 phosphorylation. J MED VIROL. 2022 JulRead more>>